Jiang Daqing, Gao Zhaohua, Cai Zhengang, Wang Meixian, He Jianjun
Department of Breast Surgery, Liaoning Province Cancer Hospital and Institute, Shenyang, Liaoning, 110042, People's Republic of China.
Department of Surgical Oncology, the First Affiliated Hospital, School of Medicine of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China.
BMC Cancer. 2015 Oct 17;15:727. doi: 10.1186/s12885-015-1742-7.
The prognostic significance of FOXP3+ tumor-infiltrating lymphocytes (TILs) in patients with breast cancer remains controversial. The aims of our meta-analysis are to evaluate its association with clinicopathological characteristics and prognostic significance in patients with breast cancer.
PubMed, Embase, Cochrane Database and the Ovid Database were systematically searched (up to April 2015). The meta-analysis was performed using hazard ratio (HR), odds ratio (OR) and 95 % confidence intervals (CI) as effect measures. Using the random-effects model, statistical analysis was performed using Stata software, version 12.0.
Seventeen studies including 8277 patients with breast cancer were analyzed. The meta-analysis indicated that the incidence difference of FOXP3+ TILs was significant when comparing the lymph node positive group to negative group (OR = 1.305, 95 % CI [1.071, 1.590]), the histological grade III group to the I-II group (OR = 3.067, 95 % CI [2.288, 4.111]), the ER positive group to the negative group (OR = 0.435, 95 % CI [0.287, 0.660]), the PR positive group to the negative group (OR = 0.493, 95 % CI [0.296, 0.822]), the HER2 positive group to the negative group (OR = 1.896, 95 % CI [1.335, 2.692]), the TNBC group to the non TNBC group (OR = 2.456, 95 % CI [1.801, 3.348]). The detection of FOXP3+ TILs was significantly correlated with the recurrence-free survival (RFS) of patients (HR = 1.752, 95 % CI [1.188-2.584]) and the overall survival (OS) of patients (HR =1.447, 95 % CI [1.037-2.019]).
Our meta-analysis demonstrates that the presence of high levels of FOXP3+ TILs is associated with prognosis for breast cancer patients and predicts lymph node metastasis, hormone receptor and HER-2 status.
FOXP3 +肿瘤浸润淋巴细胞(TILs)在乳腺癌患者中的预后意义仍存在争议。我们进行这项荟萃分析的目的是评估其与乳腺癌患者临床病理特征的相关性及预后意义。
系统检索了PubMed、Embase、Cochrane数据库和Ovid数据库(截至2015年4月)。使用风险比(HR)、比值比(OR)和95%置信区间(CI)作为效应量进行荟萃分析。采用随机效应模型,使用Stata 12.0软件进行统计分析。
分析了17项研究,共8277例乳腺癌患者。荟萃分析表明,比较淋巴结阳性组与阴性组时,FOXP3 + TILs的发生率差异有统计学意义(OR = 1.305,95%CI [1.071, 1.590]);比较组织学III级组与I-II级组时(OR = 3.067,95%CI [2.288, 4.111]);比较雌激素受体(ER)阳性组与阴性组时(OR = 0.435,95%CI [0.287, 0.660]);比较孕激素受体(PR)阳性组与阴性组时(OR = 0.493,95%CI [0.296, 0.822]);比较人表皮生长因子受体2(HER2)阳性组与阴性组时(OR = 1.896,95%CI [1.335, 2.692]);比较三阴性乳腺癌(TNBC)组与非TNBC组时(OR = 2.456,95%CI [1.801, 3.348])。FOXP3 + TILs的检测与患者无复发生存期(RFS)(HR = 1.752,95%CI [1.188 - 2.584])和总生存期(OS)(HR = 1.447,95%CI [1.037 - 2.019])显著相关。
我们的荟萃分析表明,高水平的FOXP3 + TILs与乳腺癌患者的预后相关,并可预测淋巴结转移、激素受体及HER-2状态。